** Drug developer Biohaven's BHVN.N shares fall 4.1% to $35.66
** Co posts Q4 adj. loss of $1.71 per share compared with analysts' average estimate of a loss of $1.57, according to data compiled by LSEG
** Separately, co says its experimental drug, BHV-1300, reduced Immunoglobulin G, a type of antibody, by 84% in an early-stage study to treat an autoimmune condition called Graves' disease
** Co plans to initiate a mid-stage study in patients with the disease in mid-2025
** BHVN has fallen 21.4% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。